Federal contract award
HHSN272201800011C
IGF::OT::IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541713 — Research and Development in Nanotechnology |
| PSC | AN13 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; EXPERIMENTAL DEVELOPMENT |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $10.3M |
| Current contract value | $10.3M |
| Potential contract value / ceiling | $10.3M |
| Start date | Mar 29, 2018 |
| Current end date | Sep 30, 2025 |
| Potential end date | Sep 30, 2025 |
| Latest award activity | Mar 3, 2025 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 21 of 21 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Mar 3, 2025 | P00020 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Apr 15, 2024 | P00019 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Apr 5, 2023 | P00018 | $-7 | DEOBLIGATE FUNDS FROM LINE ITEM. |
| Nov 17, 2022 | P00017 | $0 | IPP: IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| May 5, 2022 | P00016 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Oct 13, 2021 | P00015 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Jul 1, 2021 | P00014 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Apr 23, 2021 | P00013 | $1.9M | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Mar 12, 2021 | P00012 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Feb 12, 2021 | P00011 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Dec 22, 2020 | P00010 | $0 | IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Jul 21, 2020 | P00009 | $2.1M | SUPPLEMENTAL WORK-SARS-COV-2 |
| Jun 22, 2020 | P00008 | $503.9K | AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS. SARS COV-2 |
| Mar 18, 2020 | P00007 | $1.8M | AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Jun 18, 2019 | P00006 | $0 | TO MODIFY ARTICLE B.2. ESTIMATED COST AND ARTICLE B.3 ADVANCED UNDERSTANDINGS. |
| Mar 28, 2019 | P00005 | $1.9M | TO EXERCISE OPTION 1, YEAR 2 FOR PERIOD 04/1/19 - 03/31/20. |
| Feb 15, 2019 | P00004 | $0 | TO REVISE A SUBCONTRACT WITH UNIVERSITY OF MARYLAND, BALTIMORE,TO INCREASE THE NOT-TO-EXCEED AMOUNT IN THE BASE YEAR AND OPTION 1, YEAR 2. |
| Jan 28, 2019 | P00003 | $239.7K | PROVIDES FUNDS IN THE AMOUNT OF $239,683 TO CONDUCT NHP PBI STUDY AND MOUSE MODEL STUDY. |
| May 24, 2018 | P00002 | $0 | IGF::OT::IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Apr 3, 2018 | P00001 | $0 | IGF::OT::IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
| Mar 29, 2018 | 0 | $1.8M | IGF::OT::IGF AN NHP EFFICACY STUDY OF BIO 300 FOR MITIGATOR FOR DEARE-INDUCED PNEUMONITIS AND PULMONARY FIBROSIS |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.